Restless legs syndrome

Close metadata

Recommended articles:

B vitamins and diseases of the peripheral nervous system. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):75-82

Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137

Experience with the use of risdiplam in a familial case of spinal muscular atrophy 5q in patients with a homozygous deletion of the SMN1 gene and the same copy number of the SMN2 gene. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):138-141

Sleep disorders in patients with medication-overuse headache. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):93-98

Sleep disorders during pregnancy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):99-104

Modern pathogenetic treatment of rare demyelinating diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):33-36

Use of systemic steroids in hospitalized patients with COVID-19. Russian Journal of Preventive Medicine. 2024;(5):75-80

Our experience in the treatment of congenital nasal median heterotopias in children and an overview of various treatment tactics. Russian Bulletin of Otorhinolaryngology. 2024;(2):28-32

Clinical and anatomical rationale for the effectiveness of treatment of phlegmon of the floor of the oral cavity and deep cellular spaces of the neck complicated with sepsis. Russian Journal of Operative Surgery and Clinical Anatomy. 2024;(2):19-25

Perspective directions in the treatment of polycystic ovary syndrome (literature review). Russian Journal of Human Reproduction. 2024;(3):94-104

Restless legs syndrome (RLS) is seen widely in clinical practice. RLS commonly occurs at night time and presents with unpleasant or uncomfortable sensations in the legs that causes an urge to move them. This article describes the epidemiology, risk factors and pathophysiology of RLS. There is a detailed description of clinical presentations, diagnostic criteria and also management of RLS.

Keywords:

restless legs syndrome

pathogenesis

clinical presentation

treatment

augmentation

Authors:

Katunina E.A.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

ORCID: 0000-0001-5805-486X

Titova N.V.

Federal Center of Brain and Neurotechnologies;
Pirogov Russian National Research Medical University

ORCID: 0000-0002-7044-3013

Katunin D.A.

Pirogov Russian National Research Medical University;
Federal Center for Brain and Neurotechnologies

Bagmanyan S.D.

Pirogov Russian National Research Medical University

Pogorova A.R.

Pirogov Russian National Research Medical University

Received:

31.05.2020

Accepted:

03.06.2020

List of references:

Leclair-Visionneau L, Vecchierini MF, Schroder C, Charley Monaca C. French Consensus: How to diagnose restless legs syndrome. Rev Neurol (Paris). 2018;174(7-8):508–514. https://doi.org/10.1016/j.neurol.2018.08.003
Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med. 2014;15(8):860–873. https://doi.org/10.1016/j.sleep.2014.03.025
Allen RP, Walters AS, Montplaisir J, at al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;165(11):1286–1292. https://doi.org/10.1001/archinte.165.11.1286
Ohayon MM, O’Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16(4):283–295. https://doi.org/10.1016/j.smrv.2011.05.002
Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome:diagnostic criteria, special considerations and epidemiology. Sleep Med. 2003;4(2):101–119. https://doi.org/10.1016/S1389-9457(03)00010-8
Chen NH, Chuang LP, Yang CT, et al. The prevalence of restless legs syndrome in Taiwanese adults. Psychiatry Clin Neurosci. 2010;64(2):170–178. https://doi.org/10.1111/j.1440-1819.2010.02067.x
Shi Y, Yu H, Ding D, et al. Prevalence and risk factors of restless legs syndrome among Chinese adults in a rural community of Shanghai in China. PLoS One. 2015;10(3):e0121215. https://doi.org/10.1371/journal.pone.0121215
Earley CJ, Silber MH. Restless legs syndrome: understanding its consequences and the need for better treatment. Sleep Med. 2010;11(9):807–815. https://doi.org/10.1016/j.sleep.2010.07.007
Buchfuhrer MJ. Restless legs syndrome (RLS) with expansion of symptoms to the face. Sleep Med. 2008;9(2):188–190. https://doi.org/10.1016/j.sleep.2007.02.013
Allen RP, Stillman P, Myers AJ. Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: Prevalence and characteristics. Sleep Med. 2010;11(1):31–37. https://doi.org/10.1016/j.sleep.2009.03.007
Berger K, Luedemann J, Trenkwalder C, et al. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med. 2004;164(2):196–202. https://doi.org/10.1001/archinte.164.2.196
Picchietti D, Allen RP, Walters AS, et al. Restless legs syndrome: prevalence and impact in children and adolescents -- the Peds REST study. Pediatrics. 2007;120(2):253–266. https://doi.org/10.1542/peds.2006-2767
Zhang J, Lam SP, Li SX, et al. Restless legs symptoms in adolescents: epidemiology, heritability, and pubertal effects. J Psychosom Res. 2014;76(2):158–164. https://doi.org/10.1016/j.jpsychores.2013.11.017
Cesnik E, Casetta I, Turri M, et al. Transient RLS during pregnancy is a risk factor for the chronic idiopathic form. Neurology. 2010;75(23):2117–2120. https://doi.org/10.1212/WNL.0b013e318200d779
Winkelmann J, Polo O, Provini F, et al. Genetics of restless legs syndrome (RLS): State-of-the-art and future directions. Mov Disord. 2007;22:449–458. https://doi.org/10.1002/mds.21587
Allen RP, La Buda MC, Becker P, Earley CJ. Family history study of the restless legs syndrome. Sleep Med. 2002;3:3–7. https://doi.org/10.1016/S1389-9457(02)00140-5
Xiong L, Jang K, Montplaisir J, et al. Canadian restless legs syndrome twin study. Neurology. 2007;68(19):1631–1633. https://doi.org/10.1212/01.wnl.0000261016.90374.fd
Stiasny-Kolster K, Moller JC, Zschocke J, et al. Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients. Mov Disord. 2004;19(2):192–196. https://doi.org/10.1002/mds.10631
Allen RP, Connor JR, Hyland K, Earley CJ. Abnormally increased CSF 3-Ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. Sleep Med. 2009;10(1):123–128. https://doi.org/10.1016/j.sleep.2007.11.012
Connor JR, Wang XS, Allen RP, et al. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain. 2009;132:2403–2412. https://doi.org/10.1093/brain/awp125
Connor JR, Boyer PJ, Menzies SL, et al. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology. 2003;61(3):304–309. https://doi.org/10.1212/01.WNL.0000078887.16593.12
Earley CJ, Kuwabara H, Wong DF, et al. The dopamine transporter is decreased in the striatum of subjects with restless legs syndrome. Sleep. 2011;34(3):341–347. https://doi.org/10.1093/sleep/34.3.341
Ondo WG, He Y, Rajasekaran S, Le WD. Clinical correlates of 6-hydroxydopamine injections into A11 dopaminergic neurons in rats: a possible model for restless legs syndrome. Mov Disord. 2000;15(1):154–158. https://doi.org/10.1002/1531-8257(200001)15:1<154::aid-mds1025>3.0.co;2-q "> 3.0.co;2-q" target="_blank">https://doi.org/10.1002/1531-8257(200001)15:1<154::aid-mds1025>3.0.co;2-q
Zhao H, Zhu W, Pan T, et al. Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation. J Neurosci Res. 2007;85(5):1065–1076. https://doi.org/10.1002/jnr.21207
Trenkwalder C, Zieglgansberger W, Ahmedzai SH, Hogl B. Pain, opioids, and sleep: implications for restless legs syndrome treatment. Sleep Med. 2017;31:78–85. https://doi.org/10.1016/j.sleep.2016.09.017
Ferre S, Earley C, Gulyani S, Garcia-Borreguero D. In search of alternatives to dopaminergic ligands for the treatment of restless legs syndrome: iron, glutamate, and adenosine. Sleep Med. 2017;31:86–92. https://doi.org/10.1016/j.sleep.2016.08.019
Allen RP, Mignot E, Ripley B, et al. Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. Neurology. 2002;59(4):639–641. https://doi.org/10.1212/WNL.59.4.639
Allen RP, Barker PB, Wehrl FW, et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology. 2001;56(2):263–265. https://doi.org/10.1212/WNL.56.2.263
Connor JR, Wang XS, Patton SM, et al. Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology. 2004;62(9):1563–1567. https://doi.org/10.1212/01.wnl.0000123251.60485.ac
Dauvilliers Y, Winkelmann J. Restless legs syndrome: update on pathogenesis. Curr Opin Pulm Med. 2013;19(6):594-600. https://doi.org/10.1097/mcp.0b013e328365ab07
Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol. 2001;18(2):128–147. https://doi.org/10.1097/00004691-200103000-00004
Dzaja A, Wehrle R, Lancel M, Pollmacher T. Elevated estradiol plasma levels in women with restless legs during pregnancy. Sleep. 2009;32(2):169–174. https://doi.org/10.1093/sleep/32.2.169
Karroum EG, Golmard J-L, Leu-Semenescu S, Arnulf I. Sensations in restless legs syndrome. Sleep Med. 2012;13(4):402–408. https://doi.org/10.1016/j.sleep.2011.01.021
Karroum EG, Leu-Semenescu S, Arnulf I. Topography of the sensations in primary restless legs syndrome. J Neurol Sci. 2012;320(1–2):26–31. https://doi.org/10.1016/j.jns.2012.05.051
Cho YW, Song ML, Earley CJ, Allen RP. Prevalence and clinical characteristics of patients with restless legs syndrome with painful symptoms. Sleep Med. 2015;16(6):775–778. https://doi.org/10.1016/j.sleep.2014.12.024
Koo YS, Lee G-T, Lee SY, et al. Topography of sensory symptoms in patients with drug-naïve restless legs syndrome. Sleep Med. 2013;14(12):1369–1374. https://doi.org/10.1016/j.sleep.2013.09.006
Montplaisir J, Boucher S, Nicolas A, et al. Immobilization tests and periodic leg movements in sleep for the diagnosis of restless leg syndrome. Mov Disord. 1998;13(2):324–329. https://doi.org/10.1002/mds.870130220
Montplaisir J, Boucher S, Poirier G, et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12(1):61–65. https://doi.org/10.1002/mds.870120111
Ferri R, Fulda S, Allen RP, et al. World Association of Sleep Medicine (WASM) 2016 standards for recording and scoring leg movements in polysomnograms developed by a joint task force from the International and the European Restless Legs Syndrome Study Groups (IRLSSG and EURLSSG). Sleep Med. 2016;26:86–95. https://doi.org/10.1016/j.sleep.2016.10.010
Ferri R, Rundo F, Zucconi M, et al. Diagnostic accuracy of the standard and alternative periodic leg movement during sleep indices for restless legs syndrome. Sleep Med. 2016;22:97–99. https://doi.org/10.1016/j.sleep.2015.11.018
Trenkwalder C, Hening WA, Walters AS, et al. Circadian rhythm of periodic limb movements and sensory symptoms of restless legs syndrome. Mov Disord. 1999;14(1):102–110. https://doi.org/10.1002/1531-8257(199901)14:1<102::AID-MDS1017>3.0.CO;2-E "> 3.0.CO;2-E" target="_blank">https://doi.org/10.1002/1531-8257(199901)14:1<102::AID-MDS1017>3.0.CO;2-E
Haba-Rubio J, Marti-Soler H, Marques-Vidal P, et al. Prevalence and determinants of periodic limb movements in the general population: PLMS in the general population. Ann Neurol. 2016;79:464–474. https://doi.org/10.1016/S2213-2600(15)00043-0
Fantini ML, Michaud M, Gosselin N, et al. Periodic leg movements in REM sleep behavior disorder and related autonomic and EEG activation. Neurology. 2002;59(12):1889–1894. https://doi.org/10.1212/01.WNL.0000038348.94399.F6
Ferri R, Zucconi M, Rundo F, et al. Heart rate and spectral EEG changes accompanying periodic and non-periodic leg movements during sleep. Clin Neurophysiol. 2007;118(2):438–448. https://doi.org/10.1016/j.clinph.2006.10.007
Sforza E, Pichot V, Cervena K, et al. Cardiac variability and heart-rate increment as a marker of sleep fragmentation in patients with a sleep disorder: a preliminary study. Sleep. 2007;30(1):43–51. https://doi.org/10.1093/sleep/30.1.43
Pennestri MH, Montplaisir J, Colombo R, et al. Nocturnal blood pressure changes in patients with restless legs syndrome. Neurology. 2007;68(15):1213–1218. https://doi.org/10.1212/01.wnl.0000259036.89411.52
Walters AS, Rye DB. Evidence continues to mount on the relationship of restless legs syndrome/ periodic limb movements in sleep to hypertension, cardiovascular disease, and stroke. Sleep. 2009;32(5):589–597. https://doi.org/10.1093/sleep/32.5.589
Siddiqui F, Strus J, Ming X, et al. Rise of blood pressure with periodic limb movements in sleep and wakefulness. Clin Neurophysiol. 2007;118(9):1923–1930. https://doi.org/10.1016/j.clinph.2007.05.006
Cosentino FI, Arico D, Lanuzza B, et al. Absence of cardiovascular disease risk factors in restless legs syndrome. Acta Neurol Scand. 2012;125(5):319–325. https://doi.org/10.1111/j.1600-0404.2011.01563.x
Trenkwalder C, Allen R, Hogl B, et al. Restless legs syndrome associated with major diseases: a systematic review and new concept. Neurology. 2016;86(14):1336–1343. https://doi.org/10.1212/WNL.0000000000002542
Hening W, Walters AS, Allen RP, et al. Impact, diagnosis and treatment of Restless Legs Syndrome in a primary care population: REST (RLS epidemiology, symptoms and treatment) primary care study. Sleep Med. 2004;5(3):237–246. https://doi.org/10.1016/j.sleep.2004.03.006
Crochard A, El Hasnaoui A, Pouchain D, et al. Diagnostic indicators of restless legs syndrome in primary care consultations: the DESYR study. Mov Disord. 2007;22(6):791–797. https://doi.org/10.1002/mds.21325
Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria--history, rationale, description, and significance. Sleep Med. 2014;15(8):860–873. https://doi.org/10.1016/j.sleep.2014.03.025
Allen RP, Earley CJ. Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptom-onset. Sleep Med. 2000;1:11–19. https://doi.org/10.1016/s1389-9457(99)00012-x
Ondo W, Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology. 1996;47(6):1435–1441. https://doi.org/10.1212/WNL.47.6.1435
Bachmann CG, Rolke R, Scheidt U, et al. Thermal hypoaesthesia differentiates secondary restless legs syndrome associated with small fibre neuropathy from primary restless legs syndrome. Brain. 2010;133(3):762–770. https://doi.org/10.1093/brain/awq026
Merlino G, Fratticci L, Valente M, et al. Association of restless legs syndrome in type 2 diabetes: a case-control study. Sleep. 2007;30(7):866–871. https://doi.org/10.1093/sleep/30.7.866
Allen RP. Contraversies and challenges in defining etiology and pathophysiology of restless legs syndrome. Am J Med. 2007;120(1 Suppl 1):S13–21. https://doi.org/10.1016/j.amjmed.2006.11.003
Chokroverty S. Differential diagnoses of restless legs syndrome/Willis-Ekbom disease: mimics and comorbidities. Sleep Med Clin. 2015;10(3):249–262. https://doi.org/10.1016/j.jsmc.2015.05.001
Leschziner G, Gringras P. Restless Legs Syndrome. BMJ. 2012;334:e3056. https://doi.org/10.1136/bmj.e3056
Cho YW, Allen RP, Earley CJ. Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome. Sleep Med. 2016;25:16–23. https://doi.org/10.1016/j.sleep.2016.06.021
Allen RP, Adler CH, Du W, et al. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med. 2011;12(9):906–913. https://doi.org/10.1016/j.sleep.2011.06.009
Szentkiralyi A, Fendrich K, Hoffmann W, et al. Incidence of restless legs syndrome in two population-based cohort studies in Germany. Sleep Med. 2011;12(9):815–820. https://doi.org/10.1016/j.sleep.2011.06.016
Kagimura T, Nomura T, Kusumi M, et al. Prospective survey on the natural course of restless legs syndrome over two years in a closed cohort. Sleep Med. 2011;12(9):821–826. https://doi.org/10.1016/j.sleep.2011.04.012
Fulda S, Wetter TC. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain. 2008;131(4):902–917. https://doi.org/10.1093/brain/awm244
Bogan RK, Fry JM, Schmidt MH, et al. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc. 2006;81(1):17–27. https://doi.org/10.4065/81.1.17
Allen R, Becker PM, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep. 2004;27(5):907–914. https://doi.org/10.1093/sleep/27.5.907
Limousin N, Flamand M, Schroder C, Monaca CC. French Consensus: Treatment of Newly Diagnosed Restless Legs Syndrome. Rev Neurol. 2018;174(7–8):515–521. https://doi.org/10.1016/j.neurol.2018.06.002
Leu-Semenescu S, Petiau C, Charley Monaca C, Dauvilliers Y. French consensus: Augmentation syndrome in restless legs syndrome. Rev Neurol (Paris). 2018;174(7–8):532–539. https://doi.org/10.1016/j.neurol.2018.06.004
Garcia-Borreguero D, Cano-Pumarega I. New Concepts in the Management of Restless Legs Syndrome. BMJ. 2017;356:j104. https://doi.org/10.1136/bmj.j104
Voon V, Schoerling A, Wenzel S, et al. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol. 2011;11:117. https://doi.org/10.1186/1471-2377-11-117
Bogan RK, Bornemann MA, Kushida CA, et al. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. Mayo Clin Proc. 2010;85(6):512–521. https://doi.org/10.4065/mcp.2009.0700
Lal R, Ellenbogen A, Chen D, et al. A randomized, double-blind, placebocontrolled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol. 2012;35(4):165–173. https://doi.org/10.1097/wnf.0b013e318259eac8
Lee DO, Ziman RB, Perkins AT, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7(3):282–292. https://doi.org/10.5664/JCSM.1074
Walters AS, Ondo WG, Kushida CA, et al. Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol. 2009;32(6):311–320. https://doi.org/10.1097/wnf.0b013e3181b3ab16
Kushida CA, Walters AS, Becker P, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep. 2009;32(2):159–168. https://doi.org/10.1093/sleep/32.2.159
Kushida CA, Becker PM, Ellenbogen AL, C et al. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology. 2009;72(5):439–446. https://doi.org/10.1212/01.wnl.0000341770.91926.cc
Inoue Y, Hirata K, Uchimura N, et al. Gabapentin enacarbil in Japanese patients with restless legs syndrome: a 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Curr Med Res Opin. 2013;29(1):13–21. https://doi.org/10.1185/03007995.2012.746217
Bogan RK, Lee DO, Buchfuhrer MJ, et al. Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: pooled analyses from 3 trials of gabapentin enacarbil. Ann Med. 2015;47(3):269–277. https://doi.org/10.3109/07853890.2015.1025825
Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1–11. https://doi.org/10.1016/j.sleep.2016.01.017
Garcia-Borreguero D, Patrick J, DuBrava S, et al. Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep. 2014;37(4):635–643. https://doi.org/10.5665/sleep.3558
Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19(3):205–213. https://doi.org/10.1093/sleep/19.3.205
Mitterling T, Frauscher B, Falkenstetter T, et al. Is there a polysomnographic signature of augmentation in restless legs syndrome? Sleep Med. 2014;15(10):1231–1240. https://doi.org/10.1016/j.sleep.2014.05.023
Allen RP, Chen C, Garcia-Borreguero D, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014;370(7):621–631. https://doi.org/10.1056/nejmoa1303646
Allen RP, Ondo WG, Ball E, et al. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample. Sleep Med. 2011;12(5):431–439. https://doi.org/10.1016/j.sleep.2011.03.003
Hogl B, Garcia-Borreguero D, Trenkwalder C, et al. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Sleep Med. 2011;12(4):351–360. https://doi.org/10.1016/j.sleep.2010.12.007
Ferini-Strambi L. Restless legs syndrome augmentation and pramipexole treatment. Sleep Med. 2002;3(Suppl):S23–25. https://doi.org/10.1016/S1389-9457(02)00144-2
Lipford MC, Silber MH. Long-term use of pramipexole in the management of restless legs syndrome. Sleep Med. 2012;13(10):1280–1285. https://doi.org/10.1016/j.sleep.2012.08.004
Silver N, Allen RP, Senerth J, Earley CJ. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 2011;12(5):440–444. https://doi.org/10.1016/j.sleep.2010.11.002
Liu GJ, Wu L, Wang SL, et al. Incidence of augmentation in primary restless legs syndrome patients may not be that high: evidence from a systematic review and meta-analysis. Medicine (Baltimore). 2016;95(2):e2504. https://doi.org/10.1097/md.0000000000002504
Trenkwalder C, Hogl B, Benes H, Kohnen R. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med. 2008;9(5):572–574. https://doi.org/10.1016/j.sleep.2007.07.020
Garcia-Borreguero D, Silber MH, Winkelman JW, H et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1–11. https://doi.org/10.1016/j.sleep.2016.01.017

Close metadata